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Clinical Pharmacist-Led Intervention to Improve Statin Metric
for Secondary Prevention in Providence Medical Group

Health & Services

Chloe Nguyen, PharmD, Judy Wong, PharmD, BCACP, and Karen White, PharmD, BCACP

PURPOSE
The purpose of this study is to identify intervention
strategies to improve the statin metric for secondary
prevention among patients with clinical
atherosclerotic cardiovascular disease (ASCVD) in
the primary care setting at Providence Medical
Group (PMG).

BACKGROUND
• Per the Centers for Disease and Control
Prevention, cardiovascular disease is the leading
cause of morbidity and mortality in United States.
Nearly one in three American dies of stroke or
heart disease.
• According to the 2018 American College of
Cardiology/American Heart Association guideline,
high-intensity statin therapy or maximally tolerated
statin therapy is recommended for patients with
clinical ASCVD.
• Common barriers for initiating statin therapy
include previous intolerance or side effects, lack of
perceived benefits versus risks, and financial
burden.
• Currently, there is a gap in meeting the statin
metric in PMG Southern Oregon region.
• As of October 2019, 667 patients were identified
as either not being prescribed statin therapy or not
on optimized statin therapy among 8 clinics in the
PMG Southern Oregon region.

METHODS
• Different strategies will be implemented at a
single clinic, Central Point Family Medicine Clinic,
in the Southern Oregon region to demonstrate
metric improvement
Inclusion Criteria:
• Patients aged ≥ 18 years old with diagnosis of
clinical ASCVD who are either not prescribed
statin therapy or are prescribed sub-optimal statin
therapy
Exclusion Criteria:
• Pregnant women and nursing mothers
Primary Endpoints:
• Impact of academic detailing intervention on
perceived barriers on statin initiation or
optimization via pre- and post-intervention
surveys
• Percentage of approved recommendation from
providers
Secondary Endpoint:
• Percentage of statins prescribed per each
intervention strategy
Two interventions:
1. Academic detailing
• Pre- and post-surveys were collected to assess
the effectiveness of the presentation given during
providers meeting
2. Providing recommendations to provider
• Chart review for patients who met inclusion
criteria via Epic encounters

DISCUSSION

RESULTS
Intervention 1: Academic Detailing
Pre/Post Survey
Questions

Pre-survey (n=8)

Post-survey (n=7)

Often: 38%

Very often: 71%

Sometimes: 50%

Sometimes: 14%

Yes: 62%

Yes: 57%

No: 38%

No: 29%

Evidence not definitive/not sure: 0%

Evidence not definitive/not sure: 14%

Yes: 88%

Yes: 71%

No: 0%

No: 0%

Evidence not definitive/not sure: 12%

Evidence not definitive/not sure: 29%

Yes: 88%

Yes: 71%

No: 12%

No: 14%

Evidence not definitive/not sure: 0%

Evidence not definitive/not sure: 14%

Yes: 25%

Yes: 0%

No: 12%

No: 29%

Evidence not definite/not sure: 62%

Evidence not definitive/not sure: 72%

Yes: 50%

Yes: 29%

No: 25%

No: 29%

Evidence not definitive/not sure: 25%

Evidence not definitive/not sure: 43%

5-50%

10-15%

If a patient has a documented intolerance
to statin therapy in the past (e.g.
myopathy, myalgia), how likely patient
will be re-challenged with a different
statin or at a lower dose for ASCVD
secondary prevention?
Indicate whether statins causes liver
injury based on your experience and
scientific literature
Indicate whether statins cause myopathy
based on your experience and scientific
literature
Indicate whether that statins cause
rhabdomyolysis based on your
experience and scientific literature
Indicate whether statins cause cognitive
impairment based on your experience
and scientific literature

Indicate whether statins cause incident
diabetes based on your experience and
scientific literature
For ASCVD secondary prevention, how
often (in percentage %) a statin needs to
be discontinued (including drug holidays),
given patient complaints of adverse
medical events?

Intervention 2: Providing Recommendation to Providers
Baseline therapy status (n=35):
5% on suboptimal statin

20% not
prescribed
statin therapy

7% had
documented
statin
intolerance

3% not
candidates for
high intensity
statin

Results:
• 85.7% of all recommendations was approved by primary care providers
(PCP)
• 51.4% of patients will discuss statin initiation and optimization in
upcoming appointments with PCP.
• 28.5% of patients received referral to clinical pharmacy services for
ASCVD management
Percentage of statins prescribed per each intervention strategy:
Referral to clinical pharmacy for ASCVD collaborative management (n=10):
• One patient was successfully started in statin therapy via pharmacy
management
• 50% of patients declined statin initiation
• 40% of patients were unable to be reached
Discuss statin initiation/optimization in upcoming PCP appointments (n=18):
• No changes observed

Academic Detailing
• Comparing pre- and post-surveys, there was an
increased percentage of providers who are
willing to re-challenge a different statin/lower
dose for patient with documented statin
intolerance
• Survey results showed changes in providers’
beliefs when comparing pre and post survey
• Slight decrease in provider belief that statins
cause myopathy, liver injury, incidental diabetes,
cognitive impairment and rhabdomyolysis
Limitations:
• Unable to observe the content of provider
discussion with patients or frequency of shared
decision making
Providing Recommendation to Providers
• Majority of recommendations were approved by
providers. However, no specific intervention has
proven to be the most effective at increasing
statin initiation or optimization
• Very little changes were observed across all
intervention strategy selected by PCP
Limitations:
• Providers’ engagement level is variable and may
have a large impact on the results of the study
• Due to COVID-19, patients may cancel health
maintenance appointments to limit health care
exposure postponing statin discussions beyond
the timeframe of the project
• Difficult to track changes in statin prescribing if
PCP selects options to discuss therapy during
upcoming visits (3-6 months out)
• Many referred patients were unreached thus
making it challenging for pharmacist to follow-up
appropriately

NEXT STEPS
• Propose to have statin assessment as part of
annual health maintenance visits in the future for
patients with clinical ASCVD
• Implement education tools like videos, handouts,
or applications that can help to provide education
and address concerns or questions on statin
therapy
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